News

07/16/21
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
SEATTLE, WA / ACCESSWIRE / July 16, 2021 /   Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that Dr.
06/30/21
Aptevo Therapeutics' Scientists to present at Virtual Cell Engager Summit
SEATTLE, WA / June 30, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that three members of the
06/29/21
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
SEATTLE, WA / ACCESSWIRE / June 29, 2021 /   Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies today announced that the company
05/27/21
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial SEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics
05/26/21
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving CD123-Targeting Drugs Dosing Level Established For Advanced Clinical Trials SEATTLE, WA / ACCESSWIRE / May
05/11/21
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 /   Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company
04/09/21
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
SEATTLE, WA   / ACCESSWIRE / April 9, 2021 /   Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR TM and ADAPTIR-FLEX TM platform technologies, today announced that it will present
03/31/21
Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing Completes Sale of RUXIENCE Royalty Payments for Up Front Plus Milestone Payments of up to $67.5 million ; Amends Non-Dilutive Term Loan Agreement
02/09/21
Aptevo Confirms Receipt of Nominations and Proposal Notice
Stockholders Are Not Required to Take Any Action at this Time SEATTLE, WA / ACCESSWIRE / February 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™
01/11/21
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided